on PinterestA new GLP-1 drug shows promise for improving metabolic health and treating obesity-related diseases like liver disease.
on PinterestA new GLP-1 drug shows promise for improving metabolic health and treating obesity-related diseases like liver disease. camacho9999/Getty Images
- A new weight loss drug called survodutide has shown promising results in a phase 3 clinical trial.
- The drug, which stimulates GLP-1 and glucagon receptors, led to a 16.6% drop in body weight.
- Survodutide also reduced waist circumference, an indicator of metabolic health.
- Experts hope the drug will be useful for both obesity and liver disease; however, it is not yet approved for use.
Boehringer Ingelheim, a biopharmaceutical company headquartered in Ingelheim, Germany, has announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial testing survodutide.
Survodutide is a novel dual-action drug designed to treat obesity and related metabolic conditions.
The trial, conducted across multiple international sites and involving 725 adults living with obesity or overweight but without type 2 diabetes, concluded in April 2026 after 76 weeks of treatment.
Survodutide, which activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors, demonstrated significant and sustained weight loss.
Participants lost an average of 16.6% of their body weight, a significant improvement compared to just 3.2% in the placebo group.
Treatment with survodutide also showed meaningful metabolic improvements, including reductions in waist circumference, a key predictor of cardiometabolic risk.
These findings demonstrate the drug’s potential to improve overall metabolic health and address obesity-related diseases such as liver dysfunction and metabolic dysfunction-associated steatohepatitis (MASH).
Is survodutide safe and effective for weight loss?
Survodutide (BI 456906) is similar to the active ingredient tirzepatide (Mounjaro, Zepbound) in that it combines two mechanisms of action. However, it acts on a different combination of hormone receptors.
While GLP-1 receptor agonists can aid weight loss by reducing appetite and increasing fullness and satiety, survodutide goes a step further by activating glucagon receptors, which are believed to help regulate metabolic functions in the liver.
This is significant because it may allow an additional reduction in liver fat, potentially helping to reduce liver inflammation and fibrosis, two causes of obesity-related complications.
The SYNCHRONIZE-1 trial evaluated survodutide’s safety and efficacy in adults with overweight or obesity, excluding those with type 2 diabetes.
Participants received weekly injections of survodutide at doses of 3.6 milligrams or 6.0 milligrams, or a placebo, over nearly a year and a half.
The primary goals of the study were to assess the percentage change in body weight and the proportion of participants achieving at least a 5% reduction in body weight from baseline after 76 weeks of treatment.
According to the researchers, up to 85.1% of those treated with survodutide achieved at least a 5% reduction in their weight, contrasting with only 38.8% in the placebo group who reached this goal.
On average, people lost 16.6% of their weight, which was equivalent to about 39.2 pounds. The researchers further noted that this was mainly composed of fat rather than lean muscle tissue.
Another positive indicator was a significant decrease in waist circumference among the participants. Waist circumference is associated with visceral abdominal fat, which is linked to metabolic dysfunction and cardiovascular risk.
The researchers further reported that common GLP-1 gastrointestinal side effects,
Узнайте больше о пересадка волос в клинике Rubenhair.
Получите бесплатную консультацию
Проконсультируйтесь с нашими специалистами о процедуре FUE, PRP-терапии или пересадке волос.
